Neurologist Dr. Majid Fatuhi frames conditions like Alzheimer's not as a single disease but as the result of a "soup" of biological issues: toxic proteins, inflammation, and damaged blood vessels. Five key contributors are chronic stress, obesity, diabetes, hypertension, and poor sleep, which are largely manageable.

Alzheimer's is a disease of midlife. Pathological changes in the brain start to occur from around age 30, but the first noticeable cognitive symptoms typically don't manifest until one's late 60s or 70s. This highlights a crucial, multi-decade window for prevention and intervention.

Al Sandrock predicts Alzheimer's treatment will shift from managing symptoms to prevention. Like cholesterol, amyloid buildup will be monitored via routine blood tests, allowing for treatment to be administered early to prevent irreversible neuron loss before cognitive impairment begins.

The focus in Alzheimer's treatment is moving from merely slowing decline in late-stage patients to early prevention. By using anti-amyloid drugs to clear plaques before significant brain damage occurs, it may be possible to prevent the disease's onset entirely.

Voyager CEO Al Sandrock suggests the 30% average efficacy of new Alzheimer's drugs isn't uniform. Instead, some patients may see a complete halt in progression while others see no benefit. He argues the next critical step is predicting these responders, which will determine whether future therapies like anti-tau agents should be added on or used as a replacement.

The next era of CNS drug development will shift from single-target therapies for late-stage disease to early intervention. This involves using biomarkers to detect disease before symptoms appear and intervening with multimodal approaches that address multiple biological pathways simultaneously, such as amyloid, tau, and metabolic deficits in Alzheimer's.

After several tau-targeting antibodies failed, including J&J's pazdenimab, confidence in blocking extracellular tau is waning. The field's new hope is Biogen’s Biv80, an antisense drug that prevents tau protein production at the mRNA level, a mechanism that has shown potential to reverse pathology in early data.

Amyloid beta, often demonized as a toxic waste product in Alzheimer's, is fundamentally an antimicrobial peptide that protects brain cells. The problem arises not from its existence, but from the brain's inability to clear it effectively during sleep, leading to harmful accumulation.

Biogen's Phase 2 data for BIV80 is pivotal because its antisense mechanism targets Tau at the mRNA level, reducing all forms of the protein. This "turns off the faucet" approach provides a broad, definitive test of whether targeting Tau itself is a viable strategy for Alzheimer's, bypassing the complexity of its various forms.